X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
Other Suppliers
0
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. 9-(2-((-bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine
2. Adefovir Depivoxil
3. Gs 840
4. Gs-0840
5. Hepsera
6. Preveon
1. 142340-99-6
2. Hepsera
3. Preveon
4. Adefovir Pivoxil
5. Bis-pom Pmea
6. Gs-0840
7. Gs 0840
8. Gs 840
9. Gs-840
10. [2-(6-aminopurin-9-yl)ethoxymethyl-(2,2-dimethylpropanoyloxymethoxy)phosphoryl]oxymethyl 2,2-dimethylpropanoate
11. Adefovir Dipivoxil [usan]
12. Adefovir Pivoxil (jan)
13. Adefovir Di(pivaloyloxymethyl) Ester
14. Adefovir Dipivoxil (usan)
15. 9-(2-((bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine
16. (((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) 2,2-dimethylpropanoate
17. ((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphonic Acid, Diester With Hydroxymethyl Pivalate
18. Adefovir Dipivoxil (preveon, Hepsera)
19. U6q8z01514
20. Propanoic Acid, 2,2-dimethyl-, (((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphinylidene)bis(oxymethylene) Ester
21. Ncgc00164624-01
22. Adefovirdipivoxl
23. Dsstox_cid_26487
24. Dsstox_rid_81658
25. Dsstox_gsid_46487
26. ((((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphoryl)bis(oxy))bis(methylene) Bis(2,2-dimethylpropanoate)
27. Adefovir Pivoxil [jan]
28. 9-[2-[bis(pivaloyloxymethoxy)phosphorylmethoxy]ethyl]adenine
29. Youheding
30. Adefovir Dipivoxyl
31. [({[2-(6-amino-9h-purin-9-yl)ethoxy]methyl}({[(2,2-dimethylpropanoyl)oxy]methoxy})phosphoryl)oxy]methyl 2,2-dimethylpropanoate
32. Bis(pom)pmea
33. Smr002530072
34. Hepsera (tm)
35. Hepsera (tn)
36. Piv2pmea
37. Cas-142340-99-6
38. Bis(pom)-pmea
39. 9-(2-((-bis((pivaloyloxy)methoxy)phosphinyl)methoxy)ethyl)adenine
40. Unii-u6q8z01514
41. Adefovir-dipivoxil
42. Mfcd00869897
43. Adefovir Dipivoxil- Bio-x
44. Chembl922
45. Schembl29729
46. Mls003915635
47. Mls004774124
48. Dtxsid5046487
49. Chebi:31175
50. 9-(2[bis(pivaloyloxymethoxy)phosphorylmethoxy]ethyl)adenine
51. Bis(pivaloyloxymethyl)-9-(2-phosphonylmethoxyethyl)adenine
52. Adefovir Dipivoxil [vandf]
53. Bcpp000434
54. Hms3604f09
55. Hms3655i04
56. Adefovir Dipivoxil [mart.]
57. Adefovir Dipivoxil [who-dd]
58. Bcp22959
59. Hy-b0255
60. Zinc3930376
61. Tox21_112243
62. Bdbm50248359
63. S1718
64. Stl257088
65. Adefovir Dipivoxil [ema Epar]
66. Akos005145737
67. Tox21_112243_1
68. Ab07592
69. Ac-1693
70. Bcp9000232
71. Ccg-269700
72. Db00718
73. Gs-3604
74. Adefovir Dipivoxil [orange Book]
75. Ncgc00164624-02
76. Ncgc00164624-03
77. Ncgc00164624-11
78. Ba164139
79. Bcp0726000157
80. B2222
81. Ft-0631164
82. Sw219933-1
83. D01655
84. Ab01274706-01
85. Ab01274706_02
86. 340a996
87. A807894
88. Adefovir Di(pivaloyloxymethyl) Ester [mi]
89. Adefovir Dipivoxil 100 Microg/ml In Acetonitrile
90. Sr-01000931258
91. Q-101927
92. Sr-01000931258-2
93. Brd-k96159438-001-03-0
94. Adefovir Dipivoxil, Antibiotic For Culture Media Use Only
95. Bis(pivaloyloxymethyl)-9-[2-(phosphonomethoxy)ethyl]adenine
96. ((((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphoryl)-bis(oxy))bis(methylene) Bis(2,2-dimethylpropanoate)
97. (((2-(6-amino-9h-purin-9-yl)ethoxy)methyl)phosphoryl)bis(oxy)bis(methylene) Bis(2,2-dimethylpropanoate)
98. ({[2-(6-amino-9h-purin-9-yl)ethoxy]methyl}phosphoryl)bis(oxymethanediyl) Bis(2,2-dimethylpropanoate)
99. 2,2-dimethylpropanoic Acid [2-(6-aminopurin-9-yl)ethoxymethyl-[(2,2-dimethyl-1-oxopropoxy)methoxy]phosphoryl]oxymethyl Ester;adefovir Dipivoxyl
100. 3-{[2-(6-amino-9h-purin-9-yl)ethoxy]methyl}-8,8-dimethyl-3-oxido-7-oxo-2,4,6-trioxa-3?5-phosphanon-1-yl 2,2-dimethylpropanoate
101. 3-{[2-(6-amino-9h-purin-9-yl)ethoxy]methyl}-8,8-dimethyl-3-oxido-7-oxo-2,4,6-trioxa-3lambda~5~-phosphanon-1-yl 2,2-dimethylpropanoate
| Molecular Weight | 501.5 g/mol |
|---|---|
| Molecular Formula | C20H32N5O8P |
| XLogP3 | 1.8 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 12 |
| Rotatable Bond Count | 15 |
| Exact Mass | 501.19884999 g/mol |
| Monoisotopic Mass | 501.19884999 g/mol |
| Topological Polar Surface Area | 167 Ų |
| Heavy Atom Count | 34 |
| Formal Charge | 0 |
| Complexity | 706 |
| Isotope Atom Count | 0 |
| Defined Atom Stereocenter Count | 0 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
| 1 of 4 | |
|---|---|
| Drug Name | Adefovir dipivoxil |
| PubMed Health | Adefovir Dipivoxil (By mouth) |
| Drug Classes | Antiviral |
| Drug Label | HEPSERA is the tradename for adefovir dipivoxil, a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The chemical name of adefovir dipivoxil is 9-[2-[[bis[(pivaloyloxy)methoxy... |
| Active Ingredient | Adefovir dipivoxil |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 10mg |
| Market Status | Prescription |
| Company | Sigmapharm Labs |
| 2 of 4 | |
|---|---|
| Drug Name | Hepsera |
| PubMed Health | Adefovir Dipivoxil (By mouth) |
| Drug Classes | Antiviral |
| Drug Label | HEPSERA is the tradename for adefovir dipivoxil, a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The chemical name of adefovir dipivoxil is 9-[2-[[bis[(pivaloyloxy)methoxy... |
| Active Ingredient | Adefovir dipivoxil |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 10mg |
| Market Status | Prescription |
| Company | Gilead |
| 3 of 4 | |
|---|---|
| Drug Name | Adefovir dipivoxil |
| PubMed Health | Adefovir Dipivoxil (By mouth) |
| Drug Classes | Antiviral |
| Drug Label | HEPSERA is the tradename for adefovir dipivoxil, a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The chemical name of adefovir dipivoxil is 9-[2-[[bis[(pivaloyloxy)methoxy... |
| Active Ingredient | Adefovir dipivoxil |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 10mg |
| Market Status | Prescription |
| Company | Sigmapharm Labs |
| 4 of 4 | |
|---|---|
| Drug Name | Hepsera |
| PubMed Health | Adefovir Dipivoxil (By mouth) |
| Drug Classes | Antiviral |
| Drug Label | HEPSERA is the tradename for adefovir dipivoxil, a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The chemical name of adefovir dipivoxil is 9-[2-[[bis[(pivaloyloxy)methoxy... |
| Active Ingredient | Adefovir dipivoxil |
| Dosage Form | Tablet |
| Route | Oral |
| Strength | 10mg |
| Market Status | Prescription |
| Company | Gilead |
Indicated for the treatment of chronic hepatitis B in adult patients with evidence of active viral replication and either evidence of persistent elevations in serum aminotransferases (ALT or AST) or histologically active disease; this is based on histological, virological, biochemical, and serological responses in adult patients with HBeAg+ and HBeAg- chronic hepatitis B with compensated liver function, and in adult patients with clinical evidence of lamivudine-resistant hepatitis B virus with either compensated or decompensated liver function.
FDA Label
Hepsera is indicated for the treatment of chronic hepatitis B in adults with:
- compensated liver disease with evidence of active viral replication, persistently elevated serum-alanine-aminotransferase (ALT) levels and histological evidence of active liver inflammation and fibrosis. Initiation of Hepsera treatment should only be considered when the use of an alternative antiviral agent with a higher genetic barrier to resistance is not available or appropriate (see section 5. 1);
- decompensated liver disease in combination with a second agent without cross-resistance to Hepsera.
Adefovir dipivoxil a diester prodrug of adefovir. Adefovir is an acyclic nucleotide analog with activity against human hepatitis B virus (HBV). The concentration of adefovir that inhibited 50% of viral DNA synthesis (IC50) in vitro ranged from 0.2 to 2.5 μM in HBV transfected human hepatoma cell lines. The combination of adefovir with lamivudine showed additive anti-HBV activity.
Antiviral Agents
Agents used in the prophylaxis or therapy of VIRUS DISEASES. Some of the ways they may act include preventing viral replication by inhibiting viral DNA polymerase; binding to specific cell-surface receptors and inhibiting viral penetration or uncoating; inhibiting viral protein synthesis; or blocking late stages of virus assembly. (See all compounds classified as Antiviral Agents.)
Reverse Transcriptase Inhibitors
Inhibitors of reverse transcriptase (RNA-DIRECTED DNA POLYMERASE), an enzyme that synthesizes DNA on an RNA template. (See all compounds classified as Reverse Transcriptase Inhibitors.)
J05AF08
J05AF08
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
J - Antiinfectives for systemic use
J05 - Antivirals for systemic use
J05A - Direct acting antivirals
J05AF - Nucleoside and nucleotide reverse transcriptase inhibitors
J05AF08 - Adefovir dipivoxil
Absorption
The approximate oral bioavailability of adefovir from HEPSERA is 59%. When a single oral 10 mg dose is given to chronic hepatitis B patients, the peak plasma concentration (Cmax) of adefovir was 18.4 6.26 ng/mL. This occurred between 0.58 - 4 hours post dose (Tmax). The adefovir area under the plasma concentration-time curve (AUC0) was 220 70.0 ngh/mL. Food does not affect the exposure of adeforvir.
Route of Elimination
Adefovir is renally excreted by a combination of glomerular filtration and active tubular secretion.
Volume of Distribution
392 75 mL/kg [Vd at steady state, intravenous administration of 1.0 mg/kg/day]
352 9 mL/kg [Vd at steady state, intravenous administration of 3.0 mg/kg/day]
Clearance
469 99.0 mL/min [Patients with Unimpaired renal Function receiving a 10 mg single dose]
356 85.6 mL/min [Patients with mild renal impairement receiving a 10 mg single dose]
237 118 mL/min [Patients with moderate renal impairement receiving a 10 mg single dose]
91.7 51.3 mL/min [Patients with severe renal impairement receiving a 10 mg single dose]
Following oral administration, adefovir dipivoxil is rapidly converted to adefovir. 45% of the dose is recovered as adefovir in the urine over 24 hours at steady state following 10 mg oral doses. Adefovir is not a substrate of the cytochrome P450 enzymes.
Plasma adefovir concentrations declined in a biexponential manner with a terminal elimination half-life of 7.48 1.65 hours.
Adefovir dipivoxil is a prodrug of adefovir. Adefovir is an acyclic nucleotide analog of adenosine monophosphate which is phosphorylated to the active metabolite adefovir diphosphate by cellular kinases. Adefovir diphosphate inhibits HBV DNA polymerase (reverse transcriptase) by competing with the natural substrate deoxyadenosine triphosphate and by causing DNA chain termination after its incorporation into viral DNA. The inhibition constant (Ki) for adefovir diphosphate for HBV DNA polymerase was 0.1 μM. Adefovir diphosphate is a weak inhibitor of human DNA polymerases α and γ with Ki values of 1.18 μM and 0.97μM, respectively.
Market Place
